Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 528 word(s) 528 2021-08-09 11:23:37 |
2 format correct + 57 word(s) 585 2021-09-01 04:27:13 | |
3 format correct + 57 word(s) 585 2021-09-01 04:30:16 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Saliba, E. Aberrant Expression of Immunohistochemical Markers. Encyclopedia. Available online: https://encyclopedia.pub/entry/13768 (accessed on 24 February 2024).
Saliba E. Aberrant Expression of Immunohistochemical Markers. Encyclopedia. Available at: https://encyclopedia.pub/entry/13768. Accessed February 24, 2024.
Saliba, Elie. "Aberrant Expression of Immunohistochemical Markers" Encyclopedia, https://encyclopedia.pub/entry/13768 (accessed February 24, 2024).
Saliba, E. (2021, September 01). Aberrant Expression of Immunohistochemical Markers. In Encyclopedia. https://encyclopedia.pub/entry/13768
Saliba, Elie. "Aberrant Expression of Immunohistochemical Markers." Encyclopedia. Web. 01 September, 2021.
Aberrant Expression of Immunohistochemical Markers
Edit

Malignant melanoma can rarely present with unusual staining patterns. This includes aberrant expression of non-melanocytic markers and/ or lack of expression of specific melanocytic markers. 

malignant melanoma immunohistochemistry aberrant expression melanocytic markers

1. Introduction

The gold standard for melanoma diagnosis is histological examination with hematoxylin and eosin (H & E). However, malignant melanoma can exhibit varied morphologic features that make definitive diagnosis challenging, as it can be mistaken for other neoplasms. Immunohistochemical stains may be employed to aid in diagnosis, especially when the differentiation of the neoplasm is unclear or when the lesion is partially sampled. Nevertheless, rare cases of malignant melanoma can present with unusual staining patterns. This includes aberrant expression of non-melanocytic markers and/or lack of expression of the commonly used melanocytic markers.

2. Loss of Melanocytic Markers in Malignant Melanoma

The immunophenotypic profile may evolve during the course of malignant melanoma, most commonly manifesting in the loss of conventional melanocytic marker expression in metastatic lesions [1]. In fact, 1% of metastatic melanoma specimens are negative for S100. No association was found between S100 negativity and the histologic subtype or site of metastasis. [1].

It is well known that desmoplastic melanoma often stains negative for specific melanocytic markers such as Tyrosinase, HMB-45, and Melan A ( Figure 1 and Figure 2 ). S100 protein is the primary immunohistochemical stain used, with a sensitivity approaching 90% [2][3]. However, cases with focal or absent S100 staining have been reported, rendering the diagnosis of melanoma more challenging [4]. One case report of SOX10 negative desmoplastic melanoma has also been reported [5].

Figure 1. Spindle cell melanoma ((A), hematoxylin and eosin (H & E) stain ×10. Lesional cells are negative for Mart-1 ((B), immunohistochemical stain ×10) and positive for SOX10 ((C), immunohistochemical stain ×10) and NGFR ((D), immunohistochemical stain ×10).
Figure 2. Desmoplastic melanoma. Lesional cells are negative for Mart-1 ((A), immunohistochemical stain ×10) and positive for S100 ((B), immunohistochemical stain ×4) and NGFR ((C), immunohistochemical stain ×10).

An unusual case of primary melanoma with loss of staining for S100 protein, HMB-45, and Melan A, but expressed tyrosinase was also reported. Although tyrosinase is reported to be less sensitive than S100 protein, it is one of the most specific immunostains that may prove useful when the diagnosis of malignant melanoma is in doubt [6]

Another case primary melanoma on the back of a 58-year-old man was reported, in which the central portion of the tumor had lost expression of common melanocytic markers and expressed aberrant epithelial markers including pancytokeratin and CMA 5.2 [7].

3. Aberrant Expression of Non-Melanocytic Markers

The aberrant expression of desmin in melanoma is reported in many case reports. One study also found desmin expression in 24% of cases, although it might represent a referral bias from consultation cases [18].

Malignant melanoma can also aberrantly express neuroendocrine markers mainly synaptophysin, neurofilament protein, glial fibrillary acid protein and CD56. In contrast, chromogranin A expression, which usually parallels that of synaptophysin, is not reported [18,24,26]

The expression of epithelial markers such as CAM 5.2, cytokeratin AE1/AE3, and OSCAR antibody is not uncommon in melanoma, especially in cases with epithelioid cytomorphology [27,30,31]

Additionally, malignant melanoma was reported to aberrantly express several non-melanocytic markers including CD68, CD163, CD31, CD34, CD4, FLI-1, GATA3, CEA, calretinin, PAX8 and PAX2. Correlation with clinical and previous molecular findings is paramount for the correct diagnosis of these cases.  

4. Conclusions

In conclusion, malignant melanoma showing aberrant expression of immunohistochemical markers may easily be mistaken for carcinomas, lymphomas, sarcomas, and neuroendocrine tumors. Awareness by pathologists of these potential pitfalls, and appropriate use and interpretation of broad immunohistochemical markers together with the clinical history, should facilitate the diagnosis of malignant melanoma with unusual staining patterns.

References

  1. Aisner, D.L.; Maker, A.; Rosenberg, S.A.; Berman, D.M. Loss of S100 antigenicity in metastatic melanoma. Hum. Pathol. 2005, 36, 1016–1019.
  2. Busam, K.J. Cutaneous Desmoplastic Melanoma. Adv. Anat. Pathol. 2005, 12, 92–102.
  3. Ohsie, S.J.; Sarantopoulos, G.P.; Cochran, A.J.; Binder, S.W. Immunohistochemical characteristics of melanoma. J. Cutan. Pathol. 2008, 35, 433–444.
  4. Kanik, A.B.; Yaar, M.; Bhawan, J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J. Cutan. Pathol. 1996, 23, 205–210.
  5. Kooper-Johnson, S.; Mahalingam, M.; Loo, D.S. SOX-10 and S100 Negative Desmoplastic Melanoma. Am. J. Dermatopathol. 2020, 42.
  6. Shinohara, M.M.; Deubner, H.; Argenyi, Z.B. S100, HMB-45, and Melan-A negative primary melanoma. Dermatol. Online J. 2009, 15, 7.
  7. Chang, O.; Argenyi, Z. Loss of Conventional Melanocytic Markers in Malignant Melanoma and Lymph Node Metastasis; an Uncommon but Dangerous Pitfall. Am. J. Dermatopathol. 2017, 39, 760–763.
More
Information
Subjects: Dermatology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 573
Revisions: 3 times (View History)
Update Date: 24 Nov 2021
1000/1000